Marie Scully

16.7k total citations · 5 hit papers
185 papers, 7.7k citations indexed

About

Marie Scully is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Marie Scully has authored 185 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Immunology, 110 papers in Hematology and 74 papers in Genetics. Recurrent topics in Marie Scully's work include Complement system in diseases (139 papers), Platelet Disorders and Treatments (69 papers) and Renal Diseases and Glomerulopathies (50 papers). Marie Scully is often cited by papers focused on Complement system in diseases (139 papers), Platelet Disorders and Treatments (69 papers) and Renal Diseases and Glomerulopathies (50 papers). Marie Scully collaborates with scholars based in United Kingdom, United States and France. Marie Scully's co-authors include Samuel J. Machin, Flora Peyvandi, Beverley J. Hunt, Marcel Levi, Sylvia Benjamin, Vickie McDonald, Ian Mackie, Will Lester, Johanna A. Kremer Hovinga and Ri Liesner and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Marie Scully

172 papers receiving 7.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

2021 656 citations Marie Scully, Deepak Singh et al. profile →
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

2019 602 citations Marie Scully, Spero R. Cataland et al. profile →
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

2012 553 citations Marie Scully, Flora Peyvandi et al. British Journal of Haematology profile →
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

2016 429 citations Flora Peyvandi, Marie Scully et al. profile →
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

2021 364 citations Marie Scully, Will Lester et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Marie Scully	5.0k	3.9k	2.6k	1.9k	1.2k	185	7.7k
Johanna A. Kremer Hovinga	5.3k 1.1×	3.4k 0.9×	2.6k 1.0×	2.0k 1.0×	445 0.4×	173	7.0k
Paul Coppo	5.6k 1.1×	4.0k 1.0×	2.3k 0.9×	1.8k 1.0×	428 0.4×	248	7.9k
Bernhard Lämmle	8.1k 1.6×	6.8k 1.8×	3.9k 1.5×	3.6k 1.8×	981 0.8×	288	12.6k
Paul Knöbl	2.0k 0.4×	3.2k 0.8×	913 0.3×	1.2k 0.6×	497 0.4×	159	5.6k
Jeffrey L. Winters	1.8k 0.4×	2.2k 0.6×	897 0.3×	1.0k 0.5×	1.2k 1.0×	172	7.1k
Chantal Loirat	6.5k 1.3×	2.7k 0.7×	5.4k 2.1×	1.3k 0.6×	701 0.6×	202	10.8k
James B. Bussel	3.8k 0.8×	17.2k 4.5×	1.6k 0.6×	3.4k 1.8×	2.4k 2.0×	514	21.1k
Lionel Galicier	3.8k 0.8×	3.5k 0.9×	786 0.3×	962 0.5×	663 0.6×	184	7.8k
Régis Peffault de Latour	3.7k 0.8×	4.5k 1.2×	1.1k 0.4×	1.5k 0.8×	500 0.4×	384	8.6k
Fádi Fakhouri	4.4k 0.9×	1.8k 0.5×	4.2k 1.6×	1.2k 0.6×	430 0.4×	180	7.9k

Countries citing papers authored by Marie Scully

Since Specialization

Citations

This map shows the geographic impact of Marie Scully's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Scully with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Scully more than expected).

Fields of papers citing papers by Marie Scully

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Scully. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Scully. The network helps show where Marie Scully may publish in the future.

Co-authorship network of co-authors of Marie Scully

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Scully. A scholar is included among the top collaborators of Marie Scully based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Scully. Marie Scully is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stubbs, Matthew, Prabhu Gounder, Matthew Carter, et al.. (2025). Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura. Blood. 146(20). 2457–2463.

Scully, Marie, Spero R. Cataland, Paul Coppo, et al.. (2025). Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial. Blood. 146(Supplement 1). 849–849.

Taylor, A. E., et al.. (2024). Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience. Blood Advances. 8(17). 4563–4567. 6 indexed citations

Arulkumaran, Nishkantha, Mari Thomas, Matthew C. Stubbs, et al.. (2024). A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX). Scientific Reports. 14(1). 16876–16876. 1 indexed citations

Scully, Marie, et al.. (2023). Etiology and outcomes: Thrombotic microangiopathies in pregnancy. Research and Practice in Thrombosis and Haemostasis. 7(2). 100084–100084. 8 indexed citations

Thomas, Mari, Rens de Groot, Andrew J. Doyle, et al.. (2023). Alterations in the von Willebrand factor/ADAMTS-13 axis in preeclampsia. Journal of Thrombosis and Haemostasis. 22(2). 455–465. 2 indexed citations

Scully, Marie, Jerzy Windyga, Björn Mellgård, et al.. (2023). OC 14.1 Phase 3 Prospective, Randomized, Controlled, Open-Label, Multicenter, Crossover Study of Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura. Research and Practice in Thrombosis and Haemostasis. 7. 100533–100533. 3 indexed citations

Coppo, Paul, Parth Patwari, Björn Mellgård, et al.. (2023). OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study. Research and Practice in Thrombosis and Haemostasis. 7. 100534–100534. 2 indexed citations

Scully, Marie, et al.. (2023). P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE. HemaSphere. 7(S3). e2092072–e2092072. 1 indexed citations

10.

Doyle, Andrew J., Matthew Stubbs, Tina Dutt, et al.. (2022). Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood. 141(3). 285–294. 10 indexed citations

11.

Jennings, Ian, Steve Kitchen, Michael Makris, et al.. (2022). Anti‐PF4 testing for vaccine‐induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. Journal of Thrombosis and Haemostasis. 20(8). 1875–1879. 6 indexed citations

12.

Scully, Marie, Javier de la Rubia, Ara Metjian, et al.. (2022). Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study. Journal of Thrombosis and Haemostasis. 20(12). 2810–2822. 14 indexed citations

13.

Tsitsikas, Dimitris A., et al.. (2022). Pitfalls in Diagnosing Thrombotic Thrombocytopenic Purpura in Sickle Cell Disease. Journal of Clinical Medicine. 11(22). 6676–6676. 1 indexed citations

14.

Shah, Ali, Andrew G. Murchison, Matthew Benger, et al.. (2022). Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. Radiology. 305(3). 590–596. 9 indexed citations

15.

Peyvandi, Flora, Spero R. Cataland, Marie Scully, et al.. (2021). Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances. 5(8). 2137–2141. 50 indexed citations

16.

Cuker, Adam, Spero R. Cataland, Paul Coppo, et al.. (2021). Redefining outcomes in immune TTP: an international working group consensus report. Blood. 137(14). 1855–1861. 121 indexed citations

17.

Nowak, Victoria, Marie Scully, Indran Davagnanam, & Fion Bremner. (2021). Neuro-ophthalmic complications with ChAdOx1 nCoV-19 vaccine-induced thrombocytopenia and thrombosis. British Journal of Hospital Medicine. 82(10). 1–4. 1 indexed citations

18.

Fox, Thomas A., Amy A. Kirkwood, James Day, et al.. (2020). Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy. British Journal of Haematology. 191(2). 194–206. 49 indexed citations

19.

Broome, Catherine M., Alexander Röth, David J. Kuter, et al.. (2020). Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. Blood. 136(Supplement 1). 14–15. 12 indexed citations

20.

Patriquin, Christopher J., Mari Thomas, Tina Dutt, et al.. (2016). Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. British Journal of Haematology. 173(5). 779–785. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact